Substance Abuse is a premier scholarly journal published by SAGE Publications Inc, dedicated to advancing the understanding and treatment of substance use disorders. With an established presence from 1995 to 2023, the journal boasts an impressive Q1 ranking in both Medicine (miscellaneous) and Psychiatry and Mental Health, positioning it among the top tier of academic publications in these fields. Researchers and professionals will find its articles, which are grounded in rigorous empirical studies and innovative interventions, essential for addressing the complex and multifaceted nature of substance abuse. Although not an open access publication, Substance Abuse maintains a commitment to sharing valuable insights and findings, making it a vital resource for those looking to enhance their knowledge and practice. Located in Thousand Oaks, CA, this journal serves as a critical forum for international dialogue and research dissemination, ensuring that current trends and challenges in substance use are thoughtfully examined and discussed within the academic community.

Welcome to the Harm Reduction Journal, a premier academic platform published by BMC, dedicated to advancing the field of harm reduction since its inception in 2004. With an impressive track record as an Open Access publication, this journal addresses critical topics within the broad scope of medicine, psychiatry, and public health, making it indispensable for researchers, healthcare professionals, and students alike. As of 2023, it proudly holds a Q1 ranking in prestigious categories including Medicine (Miscellaneous), Psychiatry and Mental Health, and Public Health, Environmental and Occupational Health, reflecting its high impact and significance in the academic community. The journal is notable for its comprehensive discussions on innovative harm reduction strategies, public policy considerations, and evidence-based practice, fostering collaboration and knowledge exchange. With a global reach and commitment to enhancing health outcomes, the Harm Reduction Journal serves as a vital resource in the ever-evolving landscape of public health and addiction research.

Adicciones is a prominent academic journal dedicated to the fields of Medicine and Psychiatry, focusing on the multi-faceted issues surrounding addiction and substance use. Published by SOCIDROGALCOHOL in Spain, this journal has been a critical resource for researchers, clinicians, and students since its inception in 1994, with a commitment to advancing knowledge in addiction science for the benefit of public health. With an impressive impact factor that places it in the Q3 category of both Medicine (Miscellaneous) and Psychiatry and Mental Health according to 2023 rankings, Adicciones is recognized for its high-quality peer-reviewed articles that contribute to the ongoing dialogue in these vital fields. Although not currently an open-access journal, it provides valuable subscription-based access to its extensive repository of research findings and reviews, fostering a deeper understanding of the complex dynamics of addiction. The journal's continued relevance is underscored by its convergence into 2024, promising ongoing contributions that inspire new ideas and practices to combat addiction.

JOURNAL OF DRUG ISSUES, published by SAGE PUBLICATIONS INC, serves as a pivotal platform for researchers and professionals dedicated to the multifaceted exploration of drug-related topics across various fields, including health, medicine, psychiatry, and public health. With an ISSN of 0022-0426 and an E-ISSN of 1945-1369, this esteemed journal has maintained a consistent output since its inception in 1971 and is set to continue its contributions through 2024. Reflecting its high academic standards, it has achieved a Q2 ranking in Health (Social Science) and Q3 rankings in several related categories, underscoring its relevance and influence among scholarly work. The journal is indexed in Scopus, with respectable rankings in various medical and health-related disciplines, highlighting its role as an essential resource for those invested in the vigorous discourse surrounding drug issues. Although not an open-access publication, the journal ensures that access to its extensive research findings remains available to a broad audience, solidifying its importance in advancing knowledge and informing best practices in the field.

The Journal of Substance Use is a vital resource for researchers, professionals, and students in the fields of health and social sciences, published by Taylor & Francis Inc.. With an ISSN of 1465-9891 and E-ISSN of 1475-9942, this journal has been at the forefront of substance use research since its inception in 1996 and continues to provide a platform for the dissemination of innovative findings and critical analysis up to the year 2024. Ranking in the Q3 category for both Health (Social Science) and Medicine (Miscellaneous) in the 2023 quartiles, the journal encapsulates a broad spectrum of issues related to substance use, including addiction, intervention strategies, and policy implications. Although not an open-access journal, it remains accessible to a wide audience. With its substantial role in enhancing understanding and addressing the multi-faceted challenges of substance use, the Journal of Substance Use is essential for all stakeholders aiming to contribute to research and practice in this crucial area.

Substance Abuse Treatment, Prevention, and Policy is a premier open access journal published by BMC, dedicated to advancing the understanding and improvement of substance abuse treatment and prevention strategies. Since its inception in 2006, this journal has established itself as a significant resource in the fields of Health Policy and Psychiatry and Mental Health, proudly maintaining a strong reputation reflected in its 2023 Scopus rankings, which place it in the top quartiles of these categories. With an impactful focus on policy implications and evidence-based practices, the journal's comprehensive coverage supports the sharing of innovative research and perspectives aimed at mitigating substance abuse challenges worldwide. Open access since its launch, it ensures that vital research is readily available to researchers, practitioners, and students alike, facilitating collaboration and discourse in this critical area of public health. Its commitment to high-quality research is underscored by its rankings within the 78th percentile for Health Policy and 66th percentile for Psychiatry and Mental Health, highlighting its influence and relevance in addressing pressing issues in substance misuse.

Substance Abuse: Research and Treatment is a premier open-access journal published by SAGE Publications Ltd, focusing on the multifaceted aspects of substance use and its impact on mental health. Since its establishment in 2008, this journal has been dedicated to disseminating innovative research findings, case studies, and reviews that enhance understanding and treatment of substance-related disorders. With an impact factor that reflects its standing in the field, currently ranked in the Q2 category of Psychiatry and Mental Health, Substance Abuse: Research and Treatment strives to foster interdisciplinary dialogue among researchers, practitioners, and students. By making its content freely accessible, the journal encourages widespread engagement and application of evidence-based practices to mitigate substance abuse issues. The journal’s diverse global perspectives make it a vital resource for anyone invested in advancing knowledge and improving treatment outcomes in this critical area of public health.

The Journal of Dual Diagnosis, published by Routledge Journals, Taylor & Francis Ltd, is a leading interdisciplinary platform dedicated to the critical study of co-occurring mental health and substance use disorders. With its ISSN 1550-4263 and E-ISSN 1550-4271, this esteemed journal has been at the forefront of advancing research and clinical practice since its inception in 2004, and continues to serve as a vital resource until 2024. Ranked in the second quartile (Q2) in Psychiatry and Mental Health and positioned at the 64th percentile in the Scopus rankings, it emphasizes the importance of integrating care across various domains of health. Although not open access, it offers a wealth of peer-reviewed articles, case studies, and reviews suitable for researchers, practitioners, and students alike, aiming to enhance our understanding and treatment of dual diagnosis. The journal's commitment to addressing the complexities of dual disorders not only informs research but also shapes policy and clinical guidelines, making it an essential read for anyone involved in these critical areas of mental health.

ADDICTION, published by Wiley, is a highly regarded academic journal that serves the vibrant fields of Medicine and Psychiatry and Mental Health. With an impressive impact factor reflective of its significance—ranking in the top 8% and 7.5% of its categories respectively—this journal is esteemed for its rigorous peer-reviewed research which spans a wide array of topics related to addiction, including pharmacology, prevention, and treatment modalities. Since its inception in 1993, ADDICTION has continually provided a platform for innovative research, shaping the discourse and influencing clinical practices worldwide. This journal, based in the United Kingdom at a prestigious location in Hoboken, NJ, stands as a beacon for researchers, practitioners, and students alike, committed to advancing understanding and strategies to combat addiction-related challenges. Although it is not an Open Access publication, the journal's contribution to the field remains invaluable, ensuring that cutting-edge findings are disseminated widely among professionals dedicated to improving mental health outcomes.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.